ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today.
Acadia Pharmaceuticals Inc (ACAD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 699,230 | $17,690,535 | -5% | 0.01% |
| 2. | 0 | $0 | 0% | ||
| 3. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 259,109 | $6,646,145.85 | 39,317,673 | 2023-05-24 | Filing | |
| $25.65 | 24,113 | $618,498.45 | 3,610,443 | 2023-05-24 | Filing | |
| $25.51 | 28,878 | $736,787.52 | 39,058,564 | 2023-05-24 | Filing | |
| $25.51 | 2,688 | $68,581.09 | 3,586,330 | 2023-05-24 | Filing | |
| $25.27 | 218,171 | $5,513,682.96 | 39,029,686 | 2023-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.17 | 50 | $1,308.50 | 18,994 | 2026-07-30 | Filing | |
| $26.13 | 16,508 | $431,354.04 | 19,044 | 2026-07-30 | Filing | |
| $26.08 | 11,421 | $297,912.22 | 13,088 | 2026-06-26 | Filing | |
| $21.18 | 5,401 | $114,393.18 | 24,509 | 2026-05-26 | Filing | |
| $21.79 | 1,332 | $29,024.28 | 29,129 | 2026-05-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,983,198 | $50,146,450 | 0.05% | |
| 2. | 855,435 | $21,642,506 | 0.01% | |
| 3. | 789,196 | $19,966,658 | 0.01% | |
| 4. | 197,049 | $4,985,340 | 0.02% | |
| 5. | 194,948 | $4,932,184 | 0% |
News See All
ACADIA (ACAD) Upgraded to Buy After Recent Pullback
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ranks among the most profitable biotech stocks to buy now. On March 25, BofA Securities raised ACADIA Pharmaceuticals Inc.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds
TheFly reported on April 7 that RBC Capital Markets revised its outlook on ACAD, lowering its price target from $30 to $29 while keeping an Outperform rating.
9 Most Undervalued Healthcare Stocks to Buy Now
On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior.
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains
TheFly reported on February 23 that Wolfe Research initiated coverage of ACAD with an Outperform rating and a $33 price target.
10 Fastest Growing Mid Cap Stocks to Buy Now
The Federal Reserve’s pivot from higher interest rates to rate cuts is creating a meaningful shift for mid-cap stocks, according to Amy Y. Zhang, portfolio manager of the Alger Mid Cap 40 ETF.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the ACADIA Pharmaceuticals Inc.
Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. (ACAD) For 2026
TheFly reported on February 6 that Oppenheimer raised its price target on ACAD to $23 from $21 and maintained a Perform rating on the shares.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Hedge Fund Resource Center